⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines
globenewswire.com
GILD
MRK
ARCX
CGEN
VIR
3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors
businesswire.com
GILD
Cell and Gene Therapy Market Projected to Reach US$ 183.1 Billion by 2035, Supported by Expanding Global Clinical Trial Activity Says Astute Analytica
globenewswire.com
NVS
ABBV
BNTX
LLY
BMY
GILD
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
businesswire.com
GILD
Debbie's Dream Foundation: Curing Stomach Cancer Thanks Its 2025 Industry Partners for Advancing Critical Programs and Patient Support
prnewswire.com
AMGN
BMY
ARCX
AZN
GILD
JAZZ
LLY
MRK
ASTL
THTX
Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence
prnewswire.com
EDIT
NTLA
RPTX
NVS
GILD
BMY
VRTX
CRL
OCGN
Gilead Sciences to Present at Upcoming Investor Conference
businesswire.com
GILD
Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer
accessnewswire.com
GILD
FDA Approves Genentech’s Lunsumio VELO ™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
businesswire.com
GILD
PCAR
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
businesswire.com
GILD